ELLEN MARIE STRAARUP,MARIE LINDHOLM,NIELS FISKER NIELSEN
申请号：
BR112012000214
公开号：
BR112012000214A2
申请日:
2010.06.14
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
The present invention relates to oligomer compounds (oligomers), which target APO-B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL cholesterol imbalance； dyslipidemias, e.g., familial combined dyslipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, statin-resistant hypercholesterolemia； coronary artery disease (CAD), coronary heart disease (CHD), atherosclerosis.
